老年HCV感染者抗病毒治疗研究进展*

doi:10.3969/j.issn.1672-5069.2012.05.0036

摘要/Abstract

摘要： 干扰素联合利巴韦林为目前公认的抗病毒治疗丙型肝炎的首选治疗方案,但在老年慢性丙型肝炎病人,由于在治疗过程中副反应多,故中断治疗或需要减少剂量的比例高,影响了抗病毒治疗的疗效。目前研究认为：老年HCV感染者进行抗病毒治疗非常必要,通过对治疗过程中干扰素和利巴韦林副作用的监测,可提高治疗的依从性,从而获得更高的持久病毒学应答率。

王建军综述, 赵平审校. 老年HCV感染者抗病毒治疗研究进展^*[J]. 实用肝脏病杂志, 2012, 15(5): 463-465.

[1] 中华医学会传染病与寄生虫病学分会和肝病学分会.病毒性肝炎防治方案. 中华肝脏病杂志,2000,8（6）：324-329.
[2] Armstrong GL,Wasley A,Simard EP,et al. The prevalence of hepatitis C virus infection in the United states,1999 through 2002. Ann Intern Med,2006,144 （10）:705-714.
[3] Yoshizawa H,Tanaka J,Miyakawa Y. National prevention of hepatocellular carcinoma in Japan based on epidemiology of hepatitis C virus infection in the general population. Intervirology,2006,49（1-2）:7-17.
[4] Hoshida Y,Ikeda K,Kobayashi M,et al. Chronic liver disease in the extremely elderly of 80 years or more:clinical characteristics,prognosis and patient survival analysis. J Hepatol,1999,31（5）:860-866.
[5] Thabut D,Le Calvez S,Thibault V,et al. Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease Am J Gastroenterol,2006,101（6）:1260-1267
[6] Arase Y,Ikeda K,Suzuki F,Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C. Intervirology,2007,50（1）:16-23.
[7] Ikeda K,Arase Y,Kawamura Y,et al. Necessities of interferon therapy in elderly patients with chronic hepatitis C. Am J Med,2009,122（5）:479-486.
[8] Imai Y,Kasahara A,Tanaka H,et al. Interferon therapy for aged patients with chronic hepatitis C:improved survival in patients exhibiting a biochemical response. J Gastroenterol,2004,39（11）:1069-1077.
[9] Honda T,Katano Y,Shimizu J,et al. Efficacy of peginterferon-alpha-2b plus ribavirin in patients aged 65 years and older with chronic hepatitis C.Liver Int,2010,30（4）:527-537.
[10] Floreani A,Minola E,Carderi I,et al. Are elderly patients poor candidates for pegylated interferon plus ribavirin in the treatment of chronic hepatitis C J Am Geriatr Soc,2006,54（3）:549-550.
[11] Fried MW,Shiffman ML,Reddy KR,et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.N Engl J Med,2002,347（13）:975-982.
[12] Manns MP,McHutchison JG,ordon SC,et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C:a randomised trial.Lancet,2001,358（9286）:958-965.
[13] Huang CF,Yang JF,Dai CY,et al. Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C.J Infect Dis,2010,201（5）:751-759.
[14] McHutchison JG,Gordon SC,Schiff ER,et al.Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med,1998,339（21）:1485-1492.
[15] Shehab TM,Fontana RJ,Oberhelman K,et al. Effectiveness of interferon alpha-2b and ribavirin combination therapy in the treatment of naive chronic hepatitis C patients in clinical practice.Clin Gastroenterol Hepatol,2004,2（5）:425-431.
[16] Iwasaki Y,Ikeda H,Araki Y,et al. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology,2006,43（1）:54-63
[17] Nudo CG,Wong P,Hilzenrat N,et al. Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C. Can J Gastroenterol,2006,20（9）:589-592.
[18] Sezaki H,Suzuki F,Kawamura Y,et al. Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads. Dig Dis Sci,2009,54（6）:1317-1324.
[19] Reddy KR,Messinger D,Popescu M,et al. Peginterferon alpha-2a（40 kDa）and ribavirin:comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients. J Viral Hepat,2009,16（10）:724-731.
[20] Davis GL,Wong JB,McHutchison JG,et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology,2003,38（3）:645-652.
[21] Shiffman ML,Di Bisceglie AM,Lindsay KL,et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology,2004,126（4）:1015-1023.
[22] Hadziyannis SJ,Sette H,Morgan TR,et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C:a randomized study of treatment duration and ribavirin dose.Ann Intern Med,2004,140（5）:346-355.
[23] Afdhal NH,Dieterich DT,Pockros PJ,et al. Epoetin alfa maintains ribavirin dose in HCV-in- fected patients:a prospective,double-blind,randomized controlled study. Gastroenterology,2004,126（5）:1302-1311.
[24] Collantes RS,Younossi ZM. The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin. J Clin Gastroenterol,2005,39（Suppl 1）:S9-S13.
[25] Watson J. Prospects for hepatitis C virus therapeutics:levovirin and viramidine as improved derivatives of ribavirin. Curr Opin Invest Drugs,2002,3（5）:680-683.
[26] Lamarre D,Anderson PC,Bailey M,et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature,2003,426（6963）:186-189.
[27] Kwo PY. Boceprevir:a novel nonstructural 3（NS3）protease inhibitor for the treatment of chronic hepatitis C infection. Therap Adv Gastroenterol,2012,5（3）:179-188.

老年HCV感染者抗病毒治疗研究进展^*

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831.
[2]	潘美民, 李文娟, 蒋芳清, 杨丽晖, 谭永卫, 何娟, 阮建文, 蔡春琳. 慢性丙型肝炎患者血清IL-17A、FGF和IL-7水平与丙型肝炎病毒感染自发清除临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 840-843.
[3]	涂杰霞, 王安娜, 廖若汐. 干扰素α-2b与聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者疗效比较研究*[J]. 实用肝脏病杂志, 2019, 22(5): 648-651.
[4]	邓浩辉, 李晓强, 高洪波, 陈伟烈. HIV/HCV混合感染者与HCV感染者感染HCV基因型分析*[J]. 实用肝脏病杂志, 2019, 22(5): 656-659.
[5]	张梅, 石秀英, 李林娟, 薛亚妮. 肝源性糖尿病患者肝组织干扰素诱导蛋白-10表达变化*[J]. 实用肝脏病杂志, 2019, 22(5): 688-691.
[6]	白一春, 邓霁红, 梅小平. 影响聚乙二醇干扰素α-2b治疗慢性乙型肝炎患者疗效的多因素分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 490-493.
[7]	王晓晓, 陈新月. 追求乙型肝炎临床治愈的适合人群与策略[J]. 实用肝脏病杂志, 2019, 22(3): 309-312.
[8]	王宝丹, 李萌, 高于. α-干扰素治疗慢性乙型肝炎儿童疗效及其影响疗效的因素分析[J]. 实用肝脏病杂志, 2019, 22(3): 345-348.
[9]	袁春晖, 李春雨, 李红丽, 赵红娜, 王文红, 孟庆旭, 张中学. 国产聚乙二醇化干扰素α治疗HBeAg阳性慢性乙型肝炎患者疗效研究[J]. 实用肝脏病杂志, 2019, 22(3): 353-356.
[10]	刘立, 李俊义, 杜映荣, 刘春云, 李卫昆, 王辉, 李惠敏, 常丽仙, 祁燕伟. 索磷布韦/达拉他韦治疗慢性丙型肝炎患者疗效及安全性分析：一项真实世界研究[J]. 实用肝脏病杂志, 2019, 22(3): 361-364.
[11]	袁春晖,李春雨,李红丽,赵红娜,王文红,孟庆旭,张中学. IL28B基因多态性对聚乙二醇干扰素α治疗HBeAg阳性慢性乙型肝炎患者疗效的影响[J]. 实用肝脏病杂志, 2019, 22(2): 184-187.
[12]	蒋奕,刘冰. 慢性乙型肝炎与慢性丙型肝炎患者临床和肝组织病理学特征分析[J]. 实用肝脏病杂志, 2019, 22(2): 188-191.
[13]	吴静,东保吉,吴超. 慢性丙型肝炎患者外周血滤泡辅助性T淋巴细胞表面PD-1受体表达及意义研究^*[J]. 实用肝脏病杂志, 2019, 22(2): 192-195.
[14]	吴亚平,周冰清,蒋蓓莉. 慢性丙型肝炎患者发生重度肝纤维化相关因素分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 196-199.
[15]	杨珍杰,李洪涛,王剑,李霞,陈媛. 聚乙二醇化干扰素α-2a联合利巴韦林治疗代偿期丙型肝炎肝硬化患者临床疗效研究^*[J]. 实用肝脏病杂志, 2019, 22(2): 232-235.